- Advanced search
- Immuno Portal
- Malaria Portal
Compound class: Synthetic organic
Comment: Compound 8i is a multi-target receptor tyrosine kinase inhibitor . The chemical structure matches that ascribed to the Exelixis compound XL999 presented by MedKoo, but there is no peer reviewed confirmation of this nomenclature linkage.
Compound 8i does not alter c-MET activity, so its effects can be compared to those of foretinib and/or cabozantinib which are c-MET inhibitors, to help assess the contribition that inhibition of the different kinases makes to measured outcomes (e.g. antiproliferative effect).
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
|Compound 8i is potent inhibitor of key receptor tyrosine kinases (e.g. FGFR, VEGFRs and PDGFRs) that are implicated in the development and maintenance of tumour vasculature, and in the proliferation of some tumour cell types. Potent inhibition of FLT3 by compound 8i may be effective in down-modulating leukemia cell proliferation in AML.|
|Selectivity at catalytic receptors|
|Key to terms and symbols||Click column headers to sort|